Second-line treatment with docetaxel after failure of a platinum-based chemotherapy in squamous-cell head and neck cancer

Related Experiment Video

Updated: Oct 2, 2026

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
04:04

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Published on: February 12, 2017

G Numico, M Merlano

    Annals of Oncology : Official Journal of the European Society for Medical Oncology
    |March 12, 2002
    PubMed
    Abstract

    No abstract available in PubMed .

    More Related Videos

    Generation of Prostate Cancer Cell Models of Resistance to the Anti-mitotic Agent Docetaxel
    06:44

    Generation of Prostate Cancer Cell Models of Resistance to the Anti-mitotic Agent Docetaxel

    Published on: September 8, 2017

    Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment
    07:29

    Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment

    Published on: April 22, 2019

    Related Experiment Videos

    Last Updated: Oct 2, 2026

    Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
    04:04

    Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

    Published on: February 12, 2017

    Generation of Prostate Cancer Cell Models of Resistance to the Anti-mitotic Agent Docetaxel
    06:44

    Generation of Prostate Cancer Cell Models of Resistance to the Anti-mitotic Agent Docetaxel

    Published on: September 8, 2017

    Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment
    07:29

    Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment

    Published on: April 22, 2019

    Related Concept Videos

    Treatment Resistent Cancers02:56

    Treatment Resistent Cancers

    Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

    Articles linked to this work by shared authors, journal, and citation graph.

    ESMO expert consensus statements on the screening and management of financial toxicity in patients with cancer.

    ESMO open·2024

    Transformation of Cancer Care during and after the COVID Pandemic, a point of no return. The Experience of Italy.

    Journal of cancer policy·2021

    Correction to: Standard (8 weeks) vs long (12 weeks) timing to minimally-invasive surgery after NeoAdjuvant Chemoradiotherapy for rectal cancer: a multicenter randomized controlled parallel group trial (TiMiSNAR).

    BMC cancer·2020

    Standard (8 weeks) vs long (12 weeks) timing to minimally-invasive surgery after NeoAdjuvant Chemoradiotherapy for rectal cancer: a multicenter randomized controlled parallel group trial (TiMiSNAR).

    BMC cancer·2019

    Difficulties in conducting pure academic research, obstacles in data collection and quality of informations: The example of the INTERCEPTOR study.

    Oral oncology·2019

    Treatment of advanced head and neck cancer with cetuximab.

    The International journal of biological markers·2017

    Prospective circulating tumour DNA surveillance in patients with early high-risk hormone receptor positive, HER2-negative breast cancer in the TRAK-ER study.

    Annals of oncology : official journal of the European Society for Medical Oncology·2026

    Final analysis of the Neotorch study: perioperative toripalimab in combination with chemotherapy for patients with stage Ⅱ/Ⅲ resectable non-small-cell lung cancer.

    Annals of oncology : official journal of the European Society for Medical Oncology·2026

    Sacituzumab tirumotecan versus chemotherapy in previously treated locally recurrent or metastatic triple-negative breast cancer: final overall survival analysis of the Phase III OptiTROP-Breast01.

    Annals of oncology : official journal of the European Society for Medical Oncology·2026

    Efficacy and safety of risvutatug rezetecan versus gemcitabine plus docetaxel in relapsed/refractory advanced osteosarcoma: Primary results from the ARTEMIS-011 phase 3 trial.

    Annals of oncology : official journal of the European Society for Medical Oncology·2026

    Extended follow-up of tarlatamab in patients with small-cell lung cancer after platinum-based chemotherapy in the randomized phase III DeLLphi-304 study.

    Annals of oncology : official journal of the European Society for Medical Oncology·2026

    Clinical Complete Response with Dostarlimab Monotherapy in dMMR/MSI-H Locally Advanced Rectal Cancer: First Results from the Global AZUR-1 Trial.

    Annals of oncology : official journal of the European Society for Medical Oncology·2026
    See all related articles
    JoVE
    x logofacebook logolinkedin logoyoutube logo
    ABOUT JoVE
    OverviewLeadershipBlogJoVE Help Center
    AUTHORS
    Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
    LIBRARIANS
    TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
    RESEARCH
    JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
    EDUCATION
    JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
    Terms & Conditions of Use
    Privacy Policy
    Policies
    Jove
    Visualize
    Contact Us